Tag: Biopharma Perspective
-
Amylyx Turns GLP-1 Biology in the Opposite Direction
Avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, reducing Level 2 and Level 3 hypoglycemic events by 55% versus placebo in patients with post-bariatric hypoglycemia.
-
Can New Data Rescue Capricor’s Duchenne Cell Therapy at the FDA?
Capricor is submitting new 24-month upper-limb data for deramiocel after an FDA advisory committee voted against the existing efficacy evidence, reopening the regulatory debate around the DMD cell therapy.
-
Bristol Myers Squibb (BMS) Wins FDA Approval for the First CELMoD Therapy in Multiple Myeloma
The FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) as part of a three-drug regimen for previously treated multiple myeloma, marking the first approval of a CELMoD therapy.
-
Why AstraZeneca Investors Rejected a $400 Billion BMS Megadeal
Reports of a potential $400 billion AstraZeneca–Bristol Myers Squibb combination triggered a sharp market backlash and renewed questions about the value of Big Pharma megamergers.
-
Tarsus Bets Up to $800 Million on a Deuterated Vitamin A Drug
Tarsus is acquiring Alkeus for up to $800 million, gaining gildeuretinol, a Phase 3 deuterated vitamin A therapy for Stargardt disease.
-
Curium to Acquire Lantheus in an $8 Billion Radiopharma Deal
Curium’s acquisition of Lantheus could create a global radiopharma leader by combining isotope manufacturing, diagnostics, and commercial scale.
-
AstraZeneca and Bristol Myers Squibb Explore a $400 Billion Pharma Megadeal
AstraZeneca and Bristol Myers Squibb have reportedly explored a potential $400 billion merger. While no deal has been announced, the discussions highlight how U.S. expansion, portfolio diversification and long-term growth are reshaping strategic priorities across the global pharmaceutical industry.
-
Sanofi’s Pipeline Reset Signals a New Era of R&D Discipline
Sanofi’s latest pipeline review highlights a shift from expanding R&D portfolios to making more disciplined investment decisions. Here’s why that matters for the future of big pharma.
-
Why AstraZeneca Says Drug Development Must Move at “Chinese Speed”
AstraZeneca believes the next pharmaceutical race will be defined not only by scientific innovation, but also by development speed. As competition from Chinese biotech grows, AI could help accelerate drug development and improve efficiency.
-
Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.